From Ideas to Medical Progress: How Strong IP Delivers Better Health and Greater Value

By Andrew Langer, Executive Director, Coalition Against Socialized Medicine

When we celebrate Intellectual Property Month, we should consider what those property rights make possible. For patients, the consequences can be deeply personal: another treatment when the first one fails, a medicine that prevents a debilitating complication, or a cure for a disease that once meant years of suffering.

Behind each advance is a sequence that policymakers too often overlook. Intellectual property helps attract investment in innovation. Innovation expands the treatments available to patients. That medical progress creates opportunities for competition, lower costs, and better health. Protecting this cycle is essential to both American leadership and the long-term value of our healthcare spending.

At a recent RealClear Health panel, we discussed a striking observation: prescription medicines account for roughly 14 cents of every healthcare dollar. But share of spending tells only part of the story. We need to ask what that spending accomplishes. The treatments available today allow us to address conditions in ways that were previously impossible. Protecting the system that produces those advances is an essential part of making healthcare more valuable and, wherever possible, more affordable.

IP makes innovation possible

A scientific discovery is the beginning of a long journey. Before a promising idea becomes an available medicine, someone must finance development, clinical trials, regulatory review, and manufacturing. At every stage, failure remains a possibility. An exciting finding in a laboratory may never become a treatment that patients can use.

Public research, universities, private investment, and entrepreneurial companies all contribute to this process. Intellectual property helps connect those contributions. Predictable, enforceable patents give inventors and their development partners a basis for committing resources to an undertaking whose outcome may remain uncertain for years.

That protection is especially important to emerging biotechnology companies. A small firm may have no medicine on the market and little revenue. Its principal asset may be a patented discovery and the prospect of developing it into something useful. Investors must assess both the scientific risk and whether the company can protect the invention that underlies its business.

University researchers face a related challenge. A discovery can be scientifically important without being ready for clinical use. Licensing it to a company capable of undertaking further development requires confidence that the underlying rights will remain meaningful. Reliable IP helps move knowledge from the laboratory into the hands of partners equipped to turn it into a product.

This is why patent policy has consequences far beyond the courtroom. Repeated, duplicative challenges can consume resources and prolong uncertainty, especially for smaller innovators. A sound system should provide effective avenues to challenge invalid patents while preventing procedural abuse from undermining legitimate rights. Confidence in that balance helps support investment in the next generation of treatments.

Incentives for innovation efficiently direct investment to unmet need

In healthcare, the first treatment or intervention doesn’t always meet the needs of every patient. A person who cannot tolerate one medicine may respond to another. A treatment that works for one group may fail for another. A new formulation or delivery method may make effective treatment practical for someone who previously struggled to receive it.

The benefits of innovation therefore extend beyond the first treatment for a previously untreatable condition. Improvements in existing therapies can reduce side effects, simplify administration, or help additional patients. Research into new uses can expand the clinical value of an established medicine. Each meaningful advance adds to the options available to patients and their physicians.

Hepatitis C illustrates how dramatically those options can change. The CDC reports that modern oral treatments can cure more than 95 percent of patients in eight to twelve weeks. Untreated infection can lead to cirrhosis, liver cancer, and death. Developing an effective cure changes the possibilities for both individual patients and public health.

This represents medical innovation at its finest: the ability to accomplish something that the previous treatment landscape could not reliably deliver. Sustaining it requires a continuing supply of new discoveries and companies willing to undertake the difficult work of development.

Innovation creates two kinds of value

The first route from innovation to affordability is competition. Additional therapies can give physicians alternatives and give purchasers more options. Once patents and other applicable exclusivity periods expire, generic and biosimilar competition can make established innovations available at lower prices.

The FDA shows how powerful generic competition can be. Its current summary reports that a single generic competitor can be associated with a 30 percent price reduction, while five competing generics are associated with reductions approaching 85 percent. Those lower-cost products allow patients to continue benefiting from an invention after its original period of protection has ended.

This is a central feature of the American system. Temporary protection helps support the development of a new medicine. Subsequent competition can broaden access to the resulting advance. Preserving that sequence requires dependable rights during the protected period and a functioning pathway for competition afterward.

The second route to value comes through better health and the costs that effective treatment can avoid. A medicine may prevent a complication, keep someone out of the hospital, or reduce the need for other interventions. Its value also includes benefits that may never appear as savings in a pharmacy budget: less pain, greater independence, and more time with family.

That distinction matters. A treatment can improve health without reducing total spending. Another may generate savings that exceed its cost. Policymakers should evaluate those outcomes honestly, considering the medicine’s clinical benefits and effects on overall care rather than assuming that every innovation saves money or that a higher pharmacy bill necessarily means worse value.

An acquisition price tells us what it costs to purchase a medicine. It does not, by itself, tell us what the treatment accomplishes or what costs might arise without it. A healthcare system that focuses too narrowly on one budget category can miss the broader consequences of its decisions.

What fourteen cents tells us and what it leaves out

The roughly 14-cent figure offers useful context because it places medicine spending within the larger healthcare system. But a stable share does not mean that spending in dollars has stayed flat. The overall healthcare budget has grown. Nor does the spending share alone measure the health benefits delivered by each inflation-adjusted dollar.

The important question is how the combination of innovation and competition changes what patients receive. New treatments expand clinical possibilities. Competition can reduce the price of established therapies. Together, these developments can help healthcare spending accomplish more, even as policymakers continue to confront genuine affordability problems.

Consider a medicine that has become an inexpensive generic. Patients continue receiving the benefits of the original discovery, while competition makes that discovery less costly to obtain. Meanwhile, research can advance toward conditions that remain inadequately treated. The accumulated benefits of past innovation become part of the foundation on which the next generation builds.

This is the relationship we should protect: investment produces new treatments; more treatments expand options; and competition can make those options increasingly affordable. Weakening the incentives for discovery risks interrupting the process before future patients can benefit from either the breakthrough or its eventual lower-cost competitors.

Affordability also requires access. A treatment provides little practical benefit to someone who cannot obtain it. Policies should address barriers to appropriate care and promote meaningful competition, including access to generics and biosimilars. Supporting innovation and improving access are responsibilities that belong together.

China makes the stakes larger

America’s position in medical innovation is the result of sustained scientific capacity, investment, and institutions that support commercialization. Maintaining that position requires attention to the choices that determine where companies conduct research and where investors commit capital.

China’s growing role in biopharmaceutical research should sharpen that attention. IQVIA’s Global R&D Trends 2026 report describes investment and dealmaking in 2025 as increasingly concentrated in high-value science, emerging biopharma, and China-linked activity. Competition for leadership now extends well beyond manufacturing established products.

Scientific advances developed abroad can benefit American patients, and international collaboration remains important. At the same time, domestic research and development capacity has strategic value. Losing that capacity could diminish America’s ability to shape the future of medicine and increase reliance on decisions made elsewhere.

Our work on critical minerals underscores the importance of retaining productive capacity and avoiding concentrated dependence. Medicines present different markets and policy questions, but the broader lesson applies: rebuilding capabilities after they have migrated away can be difficult. American policymakers should consider the cumulative effects of choices that make domestic investment less attractive.

Reliable IP is a key part of that investment environment. Regulatory predictability and the prospect of earning a return are others. Preserving American leadership requires all of them to work together. A patent can remain legally intact while policies make developing and commercializing the protected invention economically less attractive.

That is why CASM has warned about importing foreign price controls into American healthcare. Government intervention to restrict expected returns can weaken the incentives that finance risky development. The consequences may emerge gradually, through projects that do not receive funding, companies that are never formed, or research that moves elsewhere.

Those are risks policymakers should evaluate before judging a policy solely by its projected short-term savings. Patients ultimately experience the effects through the treatments available to them, including the treatments that never arrive.

Protect the cycle that delivers tomorrow’s treatments

An agenda for driving medical innovation starts with dependable intellectual property protections and a patent system that balances legitimate review with fairness and finality. It supports the universities, small biotechnology firms, and development partners that work together to help turn early discoveries into clinical advances.

It also promotes competition. Generic and biosimilar manufacturers need effective pathways to market and a fair opportunity to compete for patients. Protecting innovation should go hand in hand with ensuring that the benefits of earlier discoveries become more widely accessible over time.

Regulatory policy should remove avoidable obstacles to development and appropriate clinical-trial participation while preserving rigorous standards for safety and effectiveness. Clear rules allow companies to plan, researchers to collaborate, and investors to assess risk. Unnecessary uncertainty consumes resources that could otherwise support useful work.

Finally, affordability policy should account for the whole patient and the whole course of care. The question is what a treatment costs, what it achieves, and how it changes the need for other services. That approach allows us to pursue lower costs where they are attainable while recognizing substantial health benefits where additional spending is justified.

Intellectual Property Month is an opportunity to explain this connection. The rights we protect today can help finance the treatments patients need tomorrow. Those treatments expand medical innovation, creating opportunities for greater competition, better health, and more value from our healthcare spending.

For CASM, preserving that cycle is a commitment to patients and to American leadership. We should build a system capable of delivering more options, more effective care, and continuing progress against disease. Strong IP, sustained innovation, and meaningful competition are essential to making that future possible.